An Open-labeled Trial of Ramipril in Patients With Migraine

This study has been completed.
Sponsor:
Information provided by:
Seoul National University Hospital
ClinicalTrials.gov Identifier:
NCT01402479
First received: July 24, 2011
Last updated: August 5, 2011
Last verified: July 2011

July 24, 2011
August 5, 2011
October 2004
July 2005   (final data collection date for primary outcome measure)
headache frequency [ Time Frame: 12 week ]
headache days
Same as current
Complete list of historical versions of study NCT01402479 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
An Open-labeled Trial of Ramipril in Patients With Migraine
An Open-labeled Trial of Ramipril in Patients With Migraine

Physiology of migraine involving renin-angiotensin systems (RAS) has been implicated. Ramipril is a broadly-used angiotensin-converting enzyme inhibitor. The investigators attempt to test the efficacy of ramipril on the prophylaxis of migraine attacks.

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Migraine With Hypertension
Drug: Ramipril
ramipril 2.5mg twice a day
Active Comparator: ramipril
open label single arm trial
Intervention: Drug: Ramipril
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
July 2005
July 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with chronic migraine are included in this study. Migraineurs should be aged 20 to 70 years old with the ability to read and understand the self-report scales, including the headache diary, used in this study.

Exclusion Criteria:

  1. Medication overuse headache are excluded in this study.
  2. Treatment with other ACEI or medication that may affect ARS
  3. Treatment with migraine prophylactic medications or anti-hypertensive agents including β adrenergic receptor or calcium channel blockers
  4. Past history of hepatic or renal dysfunction; an abnormal electrocardiography; a psychiatric disorder; a history of substance abuse; pregnancy or lactation; use of anti-psychotics, antidepressants, or anti-anxiety drugs.
Both
20 Years to 70 Years
Not Provided
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
NCT01402479
0408-131-005
No
Manho Kim, MD, PhD, Department of Neurology, Seoul National University Hospital
Seoul National University Hospital
Not Provided
Not Provided
Seoul National University Hospital
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP